Tandem Diabetes Care's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $17.1 Mil. Tandem Diabetes Care's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $398.6 Mil. Tandem Diabetes Care's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $313.6 Mil.
Tandem Diabetes Care's debt to equity for the quarter that ended in Dec. 2023 was 1.33.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Tandem Diabetes Care's Debt-to-Equity or its related term are showing as below:
TNDM'
s Debt-to-Equity Range Over the Past 10 Years
Min: -13.32 Med: 0.54 Max: 1.33
Current: 1.33
During the past 13 years, the highest Debt-to-Equity Ratio of Tandem Diabetes Care was 1.33. The lowest was -13.32. And the median was 0.54.
Tandem Diabetes Care Debt-to-Equity Historical Data
The historical data trend for Tandem Diabetes Care's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
|
Tandem Diabetes Care Annual Data
|
|
Trend |
Dec14 |
Dec15 |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Debt-to-Equity |
|
|
|
|
|
|
0.11 |
0.62 |
0.73 |
0.95 |
1.33 |
|
Tandem Diabetes Care Quarterly Data
|
|
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
| Debt-to-Equity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0.95 |
1.24 |
1.28 |
1.33 |
1.33 |
Competitive Comparison
For the Medical Devices subindustry, Tandem Diabetes Care's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tandem Diabetes Care Debt-to-Equity Distribution
For the Medical Devices & Instruments industry and Healthcare sector, Tandem Diabetes Care's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Tandem Diabetes Care's Debt-to-Equity falls into.
Tandem Diabetes Care Debt-to-Equity Calculation
Debt to Equity measures the financial leverage a company has.
Tandem Diabetes Care's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Tandem Diabetes Care's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tandem Diabetes Care (Tandem Diabetes Care) Business Description
Traded in Other Exchanges
Address
11075 Roselle Street, San Diego, CA, USA, 92121
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. Nearly three quarters of total revenue is derived from the U.S., with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days.
Executives
| Dick Allen |
director |
11045 ROSELLE STREET, SAN DIEGO CA 92121 |
| Shannon Marie Hansen |
officer: SVP & General Counsel |
C/O TANDEM DIABETES CARE, INC., 11075 ROSELLE STREET, SAN DIEGO CA 92121 |
| Leigh Vosseller |
officer: Senior Vice President and CFO |
C/O TANDEM DIABETES CARE, INC., 11075 ROSELLE STREET, SAN DIEGO CA 92121 |
| Kathleen Mcgroddy-goetz |
director |
C/O TANDEM DIABETES CARE, INC., 11075 ROSELLE STREET, SAN DIEGO CA 92121 |
| Peyton R Howell |
director |
C/O TANDEM DIABETES CARE, INC., 11075 ROSELLE STREET, SAN DIEGO CA 92121 |
| David B Berger |
officer: GENERAL COUNSEL |
11045 ROSELLE STREET, SAN DIEGO CA 92121 |
| Malagueira Joao Paulo Falcao |
director |
C/O TANDEM DIABETES CARE, INC., 11075 ROSELLE STREET, SAN DIEGO CA 92121 |
| Myoungil Cha |
director |
C/O TANDEM DIABETES CARE, INC., 11075 ROSELLE STREET, SAN DIEGO CA 92121 |
| Kim D Blickenstaff |
director, officer: PRESIDENT AND CEO |
C/O MEDIVATION, INC., 201 SPEAR STREET, 3RD FLOOR, SAN FRANCISCO CA 94105 |
| John F Sheridan |
officer: EXECUTIVE VP AND COO |
C/O TANDEM DIABETES CARE, INC., 11045 ROSELLE STREET, SAN DIEGO CA 92121 |
| Christopher J Twomey |
director |
4767 NEXUS CENTRE DRIVE, SAN DIEGO CA 92121 |
| Rebecca B Robertson |
director |
ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104 |
| James Leal |
officer: SVP, Operations |
C/O TANDEM DIABETES CARE, INC., 11075 ROSELLE STREET, SAN DIEGO CA 92121 |
| Elizabeth Anne Gasser |
officer: EVP, Chief Strategy Officer |
C/O TANDEM DIABETES CARE, INC., 11075 ROSELLE STREET, SAN DIEGO CA 92121 |
| Susan Morrison |
officer: CAO |
11045 ROSELLE STREET, SAN DIEGO CA 92121 |
Tandem Diabetes Care (Tandem Diabetes Care) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TNDM has been successfully added to your